Simulations Plus found using ticker (SLP) now have 4 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 70 and 56 with a mean TP of 61.75. With the stocks previous close at 41.31 this would indicate that there is a potential upside of 49.5%. The 50 day MA is 45.47 and the 200 moving average now moves to 49.27. The market capitalisation for the company is $837m. Company Website: https://www.simulations-plus.com
The potential market cap would be $1,251m based on the market concensus.
Simulations Plus develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems toxicology software; NAFLDsym; IPFsym; RENAsym; IPFsym; and MITOsym. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was incorporated in 1996 and is headquartered in Lancaster, California.
